{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:41:17Z","timestamp":1791499277215,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.08.045","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:11:53Z","timestamp":1787760713000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term Outcome of a DLI-based Treatment Strategy in Patients With Relapsed AML After TCD Allogeneic Stem Cell Transplantation is Hampered by GvHD and Late Relapse"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5506-6330","authenticated-orcid":false,"given":"Jule","family":"Bergsma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7006-2751","authenticated-orcid":false,"given":"Eva","family":"Argiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2385-8722","authenticated-orcid":false,"given":"Kyra","family":"Oosterink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9670-4664","authenticated-orcid":false,"given":"Peter","family":"van Balen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"van der Hem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00eblle","family":"van Lammeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Marijt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjeerd","family":"Snijders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2393-715X","authenticated-orcid":false,"given":"Jennifer","family":"Tjon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Veelken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"von dem Borne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"Halkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jtct.2026.08.045_bib0001","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/bjh.16355","article-title":"The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience","volume":"188","author":"Loke","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.045_bib0002","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2026.08.045_bib0003","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jamaoncol.2018.2091","article-title":"Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse","volume":"4","author":"Kharfan-Dabaja","year":"2018","journal-title":"JAMA Oncol"},{"issue":"31","key":"10.1016\/j.jtct.2026.08.045_bib0004","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.045_bib0005","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/bmt.2015.288","article-title":"New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT","volume":"51","author":"Chang","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.045_bib0006","article-title":"Optimization of donor lymphocyte infusion for aml relapse after allo-HCT in the era of new drugs and cell engineering","volume":"11","author":"Ye","year":"2021","journal-title":"Front Oncol."},{"issue":"12","key":"10.1016\/j.jtct.2026.08.045_bib0007","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/cac2.12376","article-title":"Optimized therapeutic strategy for patients with refractory or relapsed acute myeloid leukemia: long-term clinical outcomes and health-related quality of life assessment","volume":"42","author":"Yan","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.jtct.2026.08.045_bib0008","article-title":"Donor lymphocyte infusion is a feasible way to improve survival in patients with acute myeloid leukemia and myelodysplastic syndromes who relapse after allogeneic stem cell transplantation","author":"Minculescu","year":"2023","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jtct.2026.08.045_bib0009","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.exphem.2018.03.002","article-title":"Analysis of relapse after transplantation in acute leukemia: a comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions","volume":"62","author":"Orti","year":"2018","journal-title":"Exp Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.045_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2023.101484","article-title":"Donor lymphocyte infusion in acute myeloid leukemia","volume":"36","author":"Shah","year":"2023","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.045_bib0011","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3324\/haematol.2013.089565","article-title":"Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation","volume":"99","author":"Eefting","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.045_bib0012","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41409-018-0221-6","article-title":"Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemia","volume":"54","author":"Kato","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.045_bib0013","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/leu.2014.145","article-title":"Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis","volume":"28","author":"Stern","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.045_bib0014","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/JCO.2013.51.8571","article-title":"High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial","volume":"32","author":"Willemze","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.045_bib0015","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.045_bib0016","doi-asserted-by":"crossref","first-page":"302.e1","DOI":"10.1016\/j.jtct.2025.10.029","article-title":"Prophylactic versus preemptive donor lymphocyte infusion in refractory\/relapsed AML post-allogeneic transplant: a retrospective comparative study","volume":"32","author":"Wu","year":"2026","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.045_bib0017","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.045_bib0018","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.045_bib44","series-title":"R: A Language and Environment for Statistical Computing, version 4.4.1","year":"2024"},{"issue":"7","key":"10.1016\/j.jtct.2026.08.045_bib0019","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3390\/cancers16071278","article-title":"Donor lymphocyte infusion in the treatment of post-transplant relapse of acute myeloid leukemias and myelodysplastic syndromes significantly improves overall survival: a French\u2013Italian experience of 134 patients","volume":"16","author":"Accorsi Buttini","year":"2024","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.jtct.2026.08.045_bib0020","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.3324\/haematol.2013.100198","article-title":"Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT","volume":"99","author":"Chalandon","year":"2014","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jtct.2026.08.045_bib0021","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41409-021-01515-3","article-title":"Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia","volume":"57","author":"Schmid","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.045_bib0022","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.bbmt.2014.07.010","volume":"20","author":"Takami","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.045_bib0023","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12943-023-01889-6","article-title":"Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy","volume":"22","author":"Sauerer","year":"2023","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.045_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11010253","article-title":"Prevention and treatment of acute myeloid leukemia relapse after hematopoietic stem cell transplantation: the state of the art and future perspectives","volume":"11","author":"Leotta","year":"2022","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.jtct.2026.08.045_bib0025","doi-asserted-by":"crossref","first-page":"771.e1","DOI":"10.1016\/j.jtct.2021.05.011","article-title":"Relapse after allogeneic stem cell transplantation of acute myelogenous leukemia and myelodysplastic syndrome and the importance of second cellular therapy","volume":"27","author":"Zuanelli Brambilla","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.045_bib0026","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/s41409-023-01989-3","article-title":"Prognostic factors and clinical outcomes in patients with relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation","volume":"58","author":"Gao","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.045_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exphem.2016.12.004","article-title":"Donor lymphocyte infusions in AML and MDS: enhancing the graft-versus-leukemia effect","volume":"48","author":"Orti","year":"2017","journal-title":"Exp Hematol"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.045_bib0028","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1111\/bjh.19463","article-title":"Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia","volume":"204","author":"Kinsella","year":"2024","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.jtct.2026.08.045_bib0029","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1007\/s00277-021-04616-7","article-title":"Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion","volume":"100","author":"Shah","year":"2021","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.045_bib0030","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41408-024-01060-4","article-title":"Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients","volume":"14","author":"Schm\u00e4lter","year":"2024","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.jtct.2026.08.045_bib0031","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.3324\/haematol.2022.281877","article-title":"Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia\/myelodysplastic syndromes after a first transplantation","volume":"108","author":"Yerushalmi","year":"2023","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jtct.2026.08.045_bib0032","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3324\/haematol.2017.168716","volume":"103","author":"Schmid","year":"2018","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.045_bib0033","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/bmt.2011.130","article-title":"Predictors of health-related quality of life in patients treated with auto- and allo-SCT for hematological malignancies","volume":"47","author":"Braamse","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2026.08.045_bib0034","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.bbmt.2017.06.011","article-title":"Quality of life after allogeneic hematopoietic cell transplantation according to affected organ and severity of chronic graft-versus-host disease","volume":"23","author":"Kurosawa","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2026.08.045_bib0035","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1182\/blood-2009-06-225631","article-title":"Long-term recovery after hematopoietic cell transplantation: predictors of quality-of-life concerns","volume":"115","author":"Wong","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.045_bib0036","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.bbmt.2019.06.024","article-title":"Coping and modifiable psychosocial factors are associated with mood and quality of life in patients with chronic graft-versus-host disease","volume":"25","author":"Jacobs","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.045_bib0037","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(24)00098-X","article-title":"Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT","volume":"11","author":"Pagliuca","year":"2024","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.jtct.2026.08.045_bib0038","first-page":"2293","article-title":"Prophylactic and pre-emptive donor lymphocyte infusion in patients with acute myeloid leukemia and myelodysplastic syndrome: validation of current recommendations and proposal of a modified outcome assessment","volume":"110","author":"Vel\u00e1zquez","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2026.08.045_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.812207","article-title":"Treatment of AML relapse after allo-HCT","volume":"11","author":"Webster","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2026.08.045_bib0040","article-title":"Treatment of post-allogeneic HCT relapsed AML\/MDS with a combination of hypomethylating agent, venetoclax (HMA\/VEN) and donor lymphocyte infusion (DLI)","volume":"30","author":"Ivanov","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.045_bib0041","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3390\/cancers18010107","article-title":"Is there a future for CAR-T therapy in acute myeloid leukemia?","volume":"18","author":"Alati","year":"2026","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.jtct.2026.08.045_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051241","article-title":"Emerging CAR T cell strategies for the treatment of AML","volume":"14","author":"Vishwasrao","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.045_bib0043","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.3324\/haematol.2024.285057","article-title":"Outcomes and genetic dynamics of acute myeloid leukemia at first relapse","volume":"109","author":"Bataller","year":"2024","journal-title":"Haematologica"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672600686X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672600686X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:40:42Z","timestamp":1789731642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672600686X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":44,"alternative-id":["S266663672600686X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.045","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Outcome of a DLI-based Treatment Strategy in Patients With Relapsed AML After TCD Allogeneic Stem Cell Transplantation is Hampered by GvHD and Late Relapse","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}